JP2020180155A5 - - Google Patents

Download PDF

Info

Publication number
JP2020180155A5
JP2020180155A5 JP2020120404A JP2020120404A JP2020180155A5 JP 2020180155 A5 JP2020180155 A5 JP 2020180155A5 JP 2020120404 A JP2020120404 A JP 2020120404A JP 2020120404 A JP2020120404 A JP 2020120404A JP 2020180155 A5 JP2020180155 A5 JP 2020180155A5
Authority
JP
Japan
Prior art keywords
cell
antibody
impermeable
conjugate according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020120404A
Other languages
English (en)
Japanese (ja)
Other versions
JP7053730B2 (ja
JP2020180155A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020180155A publication Critical patent/JP2020180155A/ja
Publication of JP2020180155A5 publication Critical patent/JP2020180155A5/ja
Priority to JP2022059465A priority Critical patent/JP2022091932A/ja
Application granted granted Critical
Publication of JP7053730B2 publication Critical patent/JP7053730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020120404A 2013-08-29 2020-07-14 細胞透過性コンジュゲート及びその使用の方法 Active JP7053730B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022059465A JP2022091932A (ja) 2013-08-29 2022-03-31 細胞透過性コンジュゲート及びその使用の方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361871729P 2013-08-29 2013-08-29
US61/871,729 2013-08-29
US201461939993P 2014-02-14 2014-02-14
US61/939,993 2014-02-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016537916A Division JP6736464B2 (ja) 2013-08-29 2014-08-29 細胞透過性コンジュゲート及びその使用の方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022059465A Division JP2022091932A (ja) 2013-08-29 2022-03-31 細胞透過性コンジュゲート及びその使用の方法

Publications (3)

Publication Number Publication Date
JP2020180155A JP2020180155A (ja) 2020-11-05
JP2020180155A5 true JP2020180155A5 (https=) 2021-01-07
JP7053730B2 JP7053730B2 (ja) 2022-04-12

Family

ID=52587396

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016537916A Active JP6736464B2 (ja) 2013-08-29 2014-08-29 細胞透過性コンジュゲート及びその使用の方法
JP2020120404A Active JP7053730B2 (ja) 2013-08-29 2020-07-14 細胞透過性コンジュゲート及びその使用の方法
JP2022059465A Pending JP2022091932A (ja) 2013-08-29 2022-03-31 細胞透過性コンジュゲート及びその使用の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016537916A Active JP6736464B2 (ja) 2013-08-29 2014-08-29 細胞透過性コンジュゲート及びその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022059465A Pending JP2022091932A (ja) 2013-08-29 2022-03-31 細胞透過性コンジュゲート及びその使用の方法

Country Status (13)

Country Link
US (2) US10967070B2 (https=)
EP (1) EP3038639B1 (https=)
JP (3) JP6736464B2 (https=)
KR (2) KR20210123433A (https=)
CN (2) CN105658230B (https=)
AU (3) AU2014312031A1 (https=)
CA (1) CA2922698C (https=)
EA (1) EA201690492A1 (https=)
IL (1) IL244296A0 (https=)
MX (2) MX386030B (https=)
PH (1) PH12016500395A1 (https=)
SG (1) SG11201601443PA (https=)
WO (1) WO2015031837A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658230B (zh) 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US20160115247A1 (en) 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
UY36519A (es) 2015-01-16 2016-08-31 Hope City Anticuerpos de penetración celular
EP3331543A4 (en) * 2015-08-06 2019-03-20 City of Hope Cell-pollenizing protein antibody conjugates and methods of use
EP3331573A4 (en) * 2015-08-06 2019-02-27 City of Hope THERAPEUTIC CELL-INTERNALIZING CONJUGATES
AU2016341208A1 (en) * 2015-10-20 2018-05-10 Sorrento Therapeutics, Inc. Intracellular delivery compounds
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN108603037B (zh) * 2015-12-10 2020-11-17 希望之城 细胞穿透花青偶联抗体
KR20180059091A (ko) 2016-11-25 2018-06-04 김정수 소비자 패션선호도 기반의 가상 피팅 방법, 그 시스템 및 시스템의 작동을 제어하기 위한 제어방법
WO2018127820A2 (en) * 2017-01-04 2018-07-12 Sorrento Therapeutics Cell internalizing compounds
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF
JP7295838B2 (ja) * 2017-07-13 2023-06-21 シティ・オブ・ホープ ホスホロチオエートコンジュゲートペプチド及びその使用方法
EP3730150A4 (en) 2017-12-22 2021-10-06 Rophibio, Inc. ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
WO2019235426A1 (ja) 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
US20220125891A1 (en) 2018-06-06 2022-04-28 Osaka University Method for treating and/or preventing regnase-1-related disease
EP4153762A4 (en) * 2020-05-22 2025-05-07 City of Hope Phosphorothioate nucleic acid conjugates with DNA-editing enzymes
WO2021260054A2 (en) * 2020-06-24 2021-12-30 Sapreme Technologies B.V. Saponin derivatives with improved therapeutic window
EP4171645A2 (en) * 2020-06-24 2023-05-03 Sapreme Technologies B.V. Hydrazone-based saponin derivatives
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
EP4634373A1 (en) 2022-12-16 2025-10-22 University of Rochester Repairment of barrier dysfunction in esophagus
WO2025106120A2 (en) * 2023-06-01 2025-05-22 The Regents Of The University Of California Antibodies to stat3 decoy oligonucleotide

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
CA2118586A1 (en) 1992-07-13 1994-01-20 Bernard Malfroy-Camine Transvascular and intracellular delivery of lipidized proteins
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1995002422A1 (en) 1993-07-12 1995-01-26 Weltman Joel K Method for conjugating nucleotides and nucleosides to disulfide-, maleimide-, and thiol-containing compounds
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
ES2244006T3 (es) * 1996-08-27 2005-12-01 University Of Utah Research Foundation Bioconjugados y administracion de agentes bioactivos.
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
US6903077B1 (en) 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
US7329408B2 (en) 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
US20030158109A1 (en) 2000-11-13 2003-08-21 Klaus Giese Metastatic breast and colon cancer regulated genes
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
US20050042632A1 (en) 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
EP1668144B1 (en) * 2003-09-11 2011-08-17 Universitätsklinikum Schleswig-Holstein Campus Lübeck Nucleotide sequences promoting the trans-membrane transport of nucleic acids
AU2005217646A1 (en) 2004-02-26 2005-09-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A novel cofactor that modulates steroid receptor activities
US7714119B2 (en) 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
EP2032606B1 (en) * 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
AU2007272906B2 (en) 2006-07-12 2013-01-31 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
CA2693742A1 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009012359A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Matrix metalloprotease targeting nucleic acids
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
EP2355852A4 (en) * 2008-09-16 2015-06-24 Ge Healthcare Bio Sciences Ab CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS
US20100190691A1 (en) * 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
ES3000111T3 (en) * 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
WO2011049750A1 (en) * 2009-10-20 2011-04-28 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
NZ586074A (en) * 2010-06-10 2013-07-26 Auckland Uniservices Ltd LCLRP peptides, constructs and uses thereof
US20120122795A1 (en) 2010-08-09 2012-05-17 University Of Southern California Accelerated extension of axons
US9045750B2 (en) 2011-03-18 2015-06-02 Yuelong Ma Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
CN105658230B (zh) 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2020180155A5 (https=)
JP6965311B2 (ja) 二重特異的融合タンパク質
Smith New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics
Bélanger et al. Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases
Beirnaert et al. Bivalent llama single-domain antibody fragments against tumor necrosis factor have picomolar potencies due to intramolecular interactions
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
JP2020529863A (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
EP2915818A2 (en) Dual variable domain immunoglobulins and uses thereof
JP6156144B2 (ja) 親和性複合体に対する抗体
CN112955548B (zh) 叶酸受体α特异性抗体
US20130195871A1 (en) Dual variable domain immunoglobulins and uses thereof
SG192489A1 (en) Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
RU2662933C2 (ru) Антитела против cd26 и их применение
MX2010013239A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2024178212A (ja) Ｃｄ７３免疫チェックポイントを抑制するためのモノクローナル抗体及びその抗原結合断片並びにその使用
KR20130048242A (ko) 항-종양 항원 항체 및 이용 방법
Chen et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
JP7703027B2 (ja) 抗ｌａｇ－３のモノクローナル抗体、その抗原結合性断片及びその使用
JP2013527129A (ja) トランスフェリン受容体に対する抗体及び鉄依存性腫瘍の免疫療法のためのその使用
MX2010013236A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201333035A (zh) 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
US20120009196A1 (en) Monoclonal antibodies against hepatitis c virus core protein
JP2021509274A (ja) モノクローナル抗体およびその使用法
JP2022551662A (ja) Ｂｃｍａを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体
US20150125397A1 (en) Dual specific binding proteins directed against immune cell receptors and autoantigens